Company profile
Rein Therapeutics, Inc.
NASDAQ:RNTXBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| LTI-03 | phase2 | — | 2 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06968845 | phase2 | recruiting | 2026-02-02 | 2027-09-30 | Rein Therapeutics | A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis |
| NCT04159831 | phase2 | completed | 2020-09-26 | 2022-03-31 | Rein Therapeutics | A Study to Evaluate LTI-01 in Patients With Infected, Non-draining Pleural Effusions |
| NCT05954988 | phase1 | completed | 2023-07-06 | 2024-09-25 | Rein Therapeutics | A Study to Evaluate LTI-03 in Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF) Patients |
| NCT04233814 | phase1 | completed | 2020-01-20 | 2021-12-23 | Rein Therapeutics | Safety, Tolerability and Pharmacokinetic Study of LTI-03 in Healthy Adult Subjects |
FDA applications (0)
No records yet.